Phibro Animal Health beat earnings estimates in all 4 of the last 4 quarters with average surprise of 16.7% and a return on equity of 30%, but carries negative free cash flow at 19% of net income and a debt-to-equity ratio of 2.2 that raises value-trap warning flags alongside the attractive forward price-to-earnings of 9.7x.
Thesis pillars
- Perfect Earnings Beat Streak→Stable
- Strong Return On Equity→Stable
- Negative Free Cash Flow Red Flag→Stable
- +1 more pillar — see the Why tab for full reasoning
Phibro Animal Health Corporatio (PAHC) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $35.62, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 7.5%; Concentration risk — Product: virginiamycin.
Phibro Animal Health Corporation is a global animal health and mineral nutrition company that develops, manufactures and markets roughly 800 product lines -- antibacterials, anticoccidials, vaccines, nutritional specialty and mineral nutrition products -- in about 90 countries... Read more
Sell if holding. At $35.62, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 7.5%; Concentration risk — Product: virginiamycin. Chart setup: RSI 47 mid-range, Bollinger mid-band. Score 5.7/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: speculative.
About Phibro Animal Health Corporatio
About Phibro Animal Health Corporatio
Phibro Animal Health generated $1.30 billion in net sales for the year ended June 30, 2025, up 27% from $1.02 billion the prior year, with its Animal Health segment contributing $963 million (74% of total), Mineral Nutrition $253 million, and Performance Products $80 million. The United States accounted for $740 million, or 57% of net sales, followed by Latin America and Canada at 23%, Europe, Middle East and Africa at 12%, and Asia Pacific at 8%.
Phibro sells roughly 800 animal health and mineral nutrition product lines in about 90 countries to approximately 4,500 customers, either directly to integrated poultry, swine and cattle producers or through animal feed manufacturers, wholesalers, distributors and veterinarians. Within Animal Health, MFAs and other antibacterial and anticoccidial products made up 67% of segment net sales in fiscal 2025, boosted by the October 2024 acquisition of Zoetis's medicated feed additive portfolio for approximately $297.5 million, which contributed $208.2 million in net sales and added six manufacturing sites in the U.S., Italy and China. Phibro states it is the sole worldwide manufacturer and marketer of virginiamycin, sold under the Stafac, Eskalin and V-Max brands, protected by trade-secret know-how rather than patents. The company also manufactures vaccines at dedicated facilities in Sligo, Ireland and Guarulhos, Brazil, and it discloses that a material portion of its sales and gross profits comes from antibacterials and related products.
Show full overview
Phibro's antibacterial franchise carries a regulatory overhang distinct from ordinary competitive risk: the company flags the potential FDA withdrawal of approval for Mecadox (carbadox), a swine antibacterial, alongside broader restrictions on antibacterial use in food-producing animals tied to FDA Guidance 273 and similar initiatives globally. Because a material portion of Phibro's sales and gross profits come from antibacterials and related MFA products -- the same category that includes both Mecadox and the company's sole-manufactured virginiamycin franchise (Stafac, Eskalin, V-Max) -- a regulatory setback on a single product or ingredient class would concentrate its impact rather than being absorbed across a diversified mix of unrelated product lines.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Phibro Animal Health Corporatio's most recent 10-K filing, extracted September 6, 2026.
Recent developments
updated 2026-09-14Recent Developments — Phibro Animal Health Corporatio
Latest news
- NEWS Phibro Animal Health Corp (PAHC) Shares Fall 3.3% -- GF Value Sa - GuruFocus — GuruFocus negative
- NEWS (PAHC) Phibro Animal Health Expects Fiscal 2027 Revenue Range $1.55B - $1.60B, vs. FactSet Est of $1.55B - marketscreene — marketscreener.com neutral
- NEWS Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars - StockStory — StockStory positive
- NEWS Phibro Animal Health (PAHC) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars - FinancialContent — FinancialContent positive
Generated 2026-09-14T05:21:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductvirginiamycin10-K Item 1: 'We are the sole worldwide manufacturer and marketer of virginiamycin.'
- MEDIUMProductantibacterials and other related products10-K Item 1A: 'a material portion of our sales and gross profits are generated by antibacterials and other related products'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02MEDIUMDirector Joyce J. Lee informed the company on April 13, 2026 that she intends to resign from the board effective April 15, 2026. Her resignation was not the result of any disagreement with the company on operations, policies or practices.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $35.62, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 7.5%; Concentration risk — Product: virginiamycin. Chart setup: RSI 47 mid-range, Bollinger mid-band. Prior stop was $33.13. Score 5.7/10, moderate confidence.
Take-profit target: $38.28 (+7.5% upside). Prior stop was $33.13. Stop-loss: $33.13.
Concentration risk — Product: virginiamycin; Thin upside margin: 7.5%; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4).
Phibro Animal Health Corporatio trades at a P/E of 14.7 (forward 9.3). TrendMatrix value score: 8.3/10. Verdict: Sell.
10 analysts cover PAHC with a consensus score of 2.5/5. Average price target: $44.
What does Phibro Animal Health Corporatio do?Phibro Animal Health Corporation is a global animal health and mineral nutrition company that develops, manufactures...
Phibro Animal Health Corporation is a global animal health and mineral nutrition company that develops, manufactures and markets roughly 800 product lines -- antibacterials, anticoccidials, vaccines, nutritional specialty and mineral nutrition products -- in about 90 countries to approximately 4,500 customers. The company generated $1.30 billion in net sales for the year ended June 30, 2025, with its Animal Health segment contributing 74% of the total and the United States accounting for 57% of net sales, boosted by its October 2024 acquisition of Zoetis's medicated feed additive portfolio. Ph